Charley Lu

Charley Lu joined Taiwan Liposome Company (TT:4152) in 2011. As the Head of Business Development and Alliance Management, he led all global partnership and strategic development activities with TLC’s proprietary lipid-based nanotechnology. Prior to TLC, Charley was the Principal of Strategic Initiatives at Carantech, Inc., spinning out neuroprotective technology from the University of California, San Francisco (UCSF) for Multiple Sclerosis patients. Charley shared fundraising and operating responsibilities with the scientific founding team.Charley earned his MBA from the Johnson School at Cornell University focusing on venture capital and private equity and his MS from Northwestern University studying bioinformatics and immunology. He independently led cellular neuroimmunology research at UCSF while completing his BA in Integrative Biology with emphasis in neurobiology and endocrinology from the University of California, Berkeley. In addition to his academic ventures, Charley served as a portfolio analyst at Burrill & Company, a life science venture capital firm, evaluating investment opportunities in the biotechnology and nutraceutical industries. He was the Jonas Weil Fellow at the Johnson School and the award winner at Cornell Big Idea Business Plan competition. Mr. Lu is an active and recognized leader in the community. He has received multiple commendations for his public outreach, fundraising, and volunteering efforts at the Greater Bay Area Make-A-Wish Foundation granting wishes to children with life-threatening illnesses.